Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 402

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice

Open access
Oladunni, Fatai S., Park, Jun-Gyu, Pino, Paula A., Gonzalez, Olga, Akhter, Anwari, Allué-Guardia, Anna, Olmo-Fontánez, Angélica, Gautam, Shalini, Garcia-Vilanova, Andreu, Ye, Chengjin, Chiem, Kevin, Headley, Colwyn, Dwivedi, Varun, Parodi, Laura M., Alfson, Kendra J., Staples, Hilary M., Schami, Alyssa, Garcia, Juan I., Whigham, Alison, Platt, Roy Neal, Gazi, Michal, Martinez, Jesse, Chuba, Colin, Earley, Stephanie, Rodriguez, Oscar H., Mdaki, Stephanie Davis, Kavelish, Katrina N., Escalona, Renee, Hallam, Cory R. A., Christie, Corbett, Patterson, Jean L., Anderson, Tim J. C., Carrion, Ricardo, Dick, Edward J., Hall-Ursone, Shannan, Schlesinger, Larry S., Alvarez, Xavier, Kaushal, Deepak, Giavedoni, Luis D., Turner, Joanne, Martinez-Sobrido, Luis, Torrelles, Jordi B.·2020·Nature Communications

Abstract

Vaccine and antiviral development against SARS-CoV-2 infection or COVID-19 disease would benefit from validated small animal models. Here, we show that transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2) by the human cytokeratin 18 promoter (K18 hACE2) represent a susceptible rodent model. K18 hACE2 transgenic mice succumbed to SARS-CoV-2 infection by day 6, with virus detected in lung airway epithelium and brain. K18 ACE2 transgenic mice produced a modest TH1/2/17 cytokine storm in the lung and spleen that peaked by day 2, and an extended chemokine storm that was detected in both lungs and brain. This chemokine storm was also detected in the brain at day 6. K18 hACE2 transgenic mice are, therefore, highly susceptible to SARS-CoV-2 infection and represent a suitable animal model for the study of viral pathogenesis, and for identification and characterization of vaccines (prophylactic) and antivirals (therapeutics) for SARS-CoV-2 infection and associated severe COVID-19 disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-19891-7

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 402

Metadata

Authors
Oladunni, F. S., Park, J.-G., Pino, P. A., Gonzalez, O., Akhter, A., Allué-Guardia, A., Olmo-Fontánez, A., Gautam, S., Garcia-Vilanova, A., Ye, C., Chiem, K., Headley, C., Dwivedi, V., Parodi, L. M., Alfson, K. J., Staples, H. M., Schami, A., Garcia, J. I., Whigham, A., Platt, R. N., Gazi, M., Martinez, J., Chuba, C., Earley, S., Rodriguez, O. H., Mdaki, S. D., Kavelish, K. N., Escalona, R., Hallam, C. R. A., Christie, C., Patterson, J. L., Anderson, T. J. C., Carrion, R., Dick, E. J., Hall-Ursone, S., Schlesinger, L. S., Alvarez, X., Kaushal, D., Giavedoni, L. D., Turner, J., Martinez-Sobrido, L., & Torrelles, J. B.
Venue
Nature Communications
Published
2020-11-30
Volume
11
Issue
1
Pages
6122-6122
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3107191813
Cited by
402
References
18
FWCI
8.24
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. https://app.cochat.ai/papers/10.1038/s41467-020-19891-7
The paper
Oladunni, F. S., Park, J.-G., Pino, P. A., Gonzalez, O., Akhter, A., Allué-Guardia, A., Olmo-Fontánez, A., Gautam, S., Garcia-Vilanova, A., Ye, C., Chiem, K., Headley, C., Dwivedi, V., Parodi, L. M., Alfson, K. J., Staples, H. M., Schami, A., Garcia, J. I., Whigham, A., . . . Torrelles, J. B. (2020). Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nature Communications. https://doi.org/10.1038/s41467-020-19891-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.